Latest familial hypercholesterolemia Stories
Congressional briefing highlights results of national patient research indicating the need to improve medication adherence, access to medication and enrollment of women in clinical trials, policy recommendations
PCSK9 inhibitors could cost the health care system as much as $150 billion annually WOONSOCKET, R.I., Feb.
FIND FH Initiative Unites Industry, Advocacy Community and Academia in an Effort to Support People Affected by Familial Hypercholesterolemia (FH), a Serious Genetic Disorder THOUSAND OAKS,
Additional Data Analysis Showed Every Two Week and Monthly Dosing Regimens of Evolocumab Were Clinically Equivalent THOUSAND OAKS, Calif., Nov.
Thirteen Presentations Include New Analyses of PCSK9 Inhibitor at Upcoming American Heart Association Scientific Sessions THOUSAND OAKS, Calif., Nov.
THOUSAND OAKS, Calif., Nov. 10, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the U.S.
Data From Phase 3 RUTHERFORD-2 Study Show Evolocumab Significantly Reduced Mean LDL-C by 59-66 Percent Compared to Placebo in Patients With Heterozygous Familial Hypercholesterolemia
Represents First Marketing Authorization Application in the European Union for a PCSK9 Inhibitor THOUSAND OAKS, Calif., Sept.
- A morbid dread of being buried alive. Also spelled 'taphiphobia'.